A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein (a).

Clinical Studies - May 1, 2023 - Dec 31, 2024

Aborted

Project leader: Bilz Stefan
Members: Räss Andrea, Rickli Hans, Vetsch Susanne

Clinical Studies - Nov 1, 2022 - Mar 31, 2027

Ongoing

Project leader: Bilz Stefan
Members: Sigrist Sarah, Räss Andrea

A Multicenter, Cross-sectional Study to Characterize the Distribution of Lipoprotein(a) Levels Among Patients With Documented History of Atherosclerotic Cardiovascular Disease (ASCVD). The purpose of the study is to characterize the distribution o...

Clinical Studies - May 1, 2022 - Mar 31, 2023

Completed

Project leader: Rickli Hans
Members: Vetsch Susanne, Bilz Stefan, Räss Andrea

Weight Loss and Treatment Patterns in a Real-World Population of Adults Receiving Saxenda® for Weight Management in Routine Clinical Practice in Switzerland

Clinical Studies - Mar 25, 2022 - Jun 30, 2022

Completed

Project leader: Aczel Stefan
Members: Räss Andrea

A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of SPR001 (Tildacerfont) in Adult Subjects with Classic Congenital Adrenal Hyperplasia

Clinical Studies - Dec 1, 2021 - Dec 31, 2025

Ongoing

Project leader: Bilz Stefan
Members: Krull Ina, Räss Andrea

CONFIDENTIAL Page 1 of 112 A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of SPR001 (Tildacerfont) in Reducing Supraphysiologic Glucocorticoid Use in Adult Subjects with Classic Congenital Adrenal Hyperplasia

Clinical Studies - Dec 1, 2021 - Dec 31, 2025

Ongoing

Project leader: Bilz Stefan
Members: Krull Ina, Räss Andrea

Post-marketing surveillance study to evaluate the clinical utility of ACRODAT® in an international, multicentre, randomised, non-interventional study

Clinical Studies - Dec 1, 2021 - Dec 31, 2025

Aborted

Project leader: Bilz Stefan
Members: Räss Andrea, Grillmayr Victoria

Personal Health Coaching für Patient*innen mit Diabetes Typ 2

Clinical Studies - Apr 1, 2021 - Dec 31, 2030

Ongoing

Project leader: Bilz Stefan
Members: Räss Andrea, Grillmayr Victoria

Targeted correction of plasma sodium levels in hospitalized patients with hyponatremia: a randomized, controlled, parallel-group trial with blinded outcome assessment

Clinical Studies - Feb 1, 2021 - Dec 31, 2025

Ongoing

Project leader: Bilz Stefan
Members: Bontognali Martina, Räss Andrea, Rothlin Silvia, Grillmayr Victoria

High Dose Vitamin-D-substitution in Patients with COVID-19: a randomized, double blind, placebo controlled, multi-centre Study. The objective of the study is to test the hypothesis that patients with vitamin D deficiency suffering from COVID-19 trea...

Clinical Studies - Jan 25, 2021 - Dec 31, 2021

Automatically Closed

Project leader: Brändle Michael
Members: Bloch Nando, Räss Andrea

A randomized, double-blind, placebo-controlled, multi-Center Phase 2 study to assess the efficacy and safety of oral BAY 2327949 in patients with clinical diagnosis of chronic kidney disease due to diabetes or hypertension and at least one cardiovasc...

Clinical Studies - Dec 1, 2020 - Dec 31, 2021

Aborted

Project leader: Bilz Stefan
Members: Räss Andrea, Grillmayr Victoria

Nicht-interventionelle, multizentrische, prospektive Studie zur Erfassung der glykämischen Variabilität in Diabetes mellitus Typ 1 Patienten nach Umstellung auf Insulin glargin 300 E/ml (Gla-300) (wegen unzureichender glykämischer Kontrolle) in Kom...

Clinical Studies - Dec 1, 2020 - Mar 1, 2022

Automatically Closed

Project leader: Bilz Stefan
Members: Räss Andrea, Grillmayr Victoria

An international, multicenter, prospective, non-interventional registry for patients with X-linked hypophosphatemia (XLH)

Clinical Studies - Dec 1, 2020 - Dec 31, 2030

Ongoing

Project leader: Bilz Stefan
Members: Räss Andrea, Grillmayr Victoria

The primary objective is to investigate the glycaemic control in adult patients with type 2 diabetes (T2D) who have not previously been treated with injectable glucose-lowering medication and who initiate treatment with oral semaglutide according to...

Clinical Studies - Sep 1, 2020 - Sep 1, 2022

Automatically Closed

Project leader: Bilz Stefan
Members: Drescher Tilman, Grillmayr Victoria, Räss Andrea

A randomised, Double-Blind, Placebo-Controlled, Dose-Finding Phase IIb Study to assess the efficacy and safety of orally administered Epeleuton in Patients with Hypertriglyceridemia and Typ 2 Diabetes. Short Title: TRIglyceride And Glucose contro...

Clinical Studies - Sep 1, 2020 - Aug 31, 2021

Automatically Closed

Project leader: Bilz Stefan
Members: Veraguth Katja, Quarella Marino, Räss Andrea, Grillmayr Victoria

Clinical Studies - Aug 1, 2020 - Dec 31, 2029

Ongoing

Project leader: Bilz Stefan
Members: Semela David, Räss Andrea, Stillhard Roman

To assess the characteristics and management of very high risk and high risk patients requiring lipid modifying therapies and the use of healthcare resources associated with current patient management strategies, particularly with respect to the prev...

Clinical Studies - Jul 1, 2020 - Jun 30, 2022

Automatically Closed

Project leader: Bilz Stefan
Members: Räss Andrea, Grillmayr Victoria

Primary hyperparathyroidism and familial hypocalciuric hypercalcemia: evaluation of calciuria in spot urine and 24-hours urine sample

Clinical Studies - Jul 1, 2020 - Dec 31, 2024

Ongoing

Project leader: Bilz Stefan
Members: Siegenthaler Martin, Koster Markus, Räss Andrea, Grillmayr Victoria

Akromegalie ist ein sehr seltene Erkrankungen, deren Behandlung in vielerlei Hinsicht noch nicht ausreichend erforscht ist. Eine effektive Erforschung dieser Erkrankung setzt voraus, dass möglichst umfangreiche Informationen über möglichst viele Pati...

Clinical Studies - Sep 6, 2019 - Dec 31, 2029

Ongoing

Project leader: Krull Ina
Members: Bilz Stefan, Räss Andrea

Effect and safety of semaglutide 2.4 mg once-weekly in subjects with overweight or obesity who have reached target dose during run-in period

Clinical Studies - Jun 5, 2018 - May 31, 2020

Completed

Project leader: Bilz Stefan
Members: Sigrist Sarah, Aczel Stefan, Räss Andrea